Novo Nordisk's Wegovy Sales Beat Expectations
The pharmaceutical giant’s blockbuster weight-loss drug beat sales expectations in the third quarter, sending shares higher in early trade.
Read more at The Wall Street Journal
-
Novo Nordisk shares jump 8% after Wegovy sales beat expectations
Business - CNBC - November 6 -
The Novo Nordisk scientist behind Ozempic, Wegovy weight loss research
Top stories - CBS News - November 4 -
Novo Nordisk Launches Wegovy Weight-Loss Drug in China
Business - The Wall Street Journal - 2 days ago -
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
Business - CNBC - October 23 -
Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
Business - CNBC - October 30 -
With Novo Nordisk success, is there a "Nokia risk" for Denmark?
Top stories - CBS News - November 3 -
Danone Sales Growth Beats Market Expectations
Business - The Wall Street Journal - October 24 -
Novo Nordisk's obesity-fighting drugs fatten Denmark's economy
Top stories - CBS News - November 3
More from The Wall Street Journal
-
Boohoo Changes Chairman as Frasers Calls For Removal
Business - The Wall Street Journal - 5 hours ago -
Resolute Mining Says CEO, Employees Released From Detention in Mali
Business - The Wall Street Journal - 7 hours ago -
JD Sports Expects Profit at Lower End of Guidance
Business - The Wall Street Journal - 7 hours ago -
Novartis Lifts Sales Outlook on Key Drugs, Pipeline Portfolio
Business - The Wall Street Journal - 8 hours ago -
Julius Baer Assets Rise as Inflows Accelerate
Business - The Wall Street Journal - 8 hours ago
